<DOC>
	<DOCNO>NCT00843037</DOCNO>
	<brief_summary>This open-label phase II study investigational drug , sunitinib malate patient advance malignant paraganglioma phaeochromocytoma cancer . Paragangliomas ( PGs ) tumours arise para-sympathetic system head neck sympathetic system thorax abdomen . Paragangliomas secrete hormone ( catecholamine ) adrenal gland call pheochromocytoma ( PCs ) . In study , patient whose disease advance spread despite prior standard therapy , receive sunitinib 4-weeks follow 2-week rest period , 12 month , absence disease progression . Sunitinib investigational drug , show shrink tumour several tumour model . The study evaluate efficacy well toxicity profile sunitinib use alternative treatment patient PG/PC tumour .</brief_summary>
	<brief_title>Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma</brief_title>
	<detailed_description>This study single arm , open-label , phase II trial sunitinib patient metastatic locally advanced malignant paraganglioma phaeochromocytoma . Oral sunitinib ( 50 mg ) administer patient daily first four week six week study cycle , follow 2-week rest . Patients assess response study treatment use MRI/CT scan well bio-chemical test , receive study treatment 12 month disease progression . Primary study outcome include : To assess efficacy ( response rate ) sunitinib give orally daily 4 every 6 week patient advance metastatic paraganglioma/ pheochromocytoma . To assess toxicity sunitinib patient advance metastatic paraganglioma/ pheochromocytoma . To document effect sunitinib marker biochemical activity advance metastatic paraganglioma/ pheochromocytoma .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis malignant paraganglioma pheochromocytoma either evidence metastases unresectability . Evidence recent disease progression ( radiological , biochemical , symptomatic ) . Measurable disease define measure least one dimension minimum size 10 mm CT scan . ECOG 02 . Life expectancy great 24 week . Age &gt; 18 year . Patients must normal organ marrow function . Patients must PT/INR/PTT within 1.2 X upper limit Patients may prior radiation therapy . A minimum 28 day must elapse end radiotherapy registration onto study . Previous Surgery : Previous major surgery permit provide least 28 day prior patient registration Laboratory Requirements Parameter Limit granulocyte ( AGC ) &gt; 1.5 x 109/L platelet &gt; 100 x 109/L bilirubin &lt; 1.5XULN AST ALT &lt; 2.5 x ULN Amylase &lt; 1.5XULN Lipase &lt; 1.5XULN Calcium &lt; 3 mmol/L creatinine &lt; 2.0XULN History malignancy . Patients know brain metastasis . History allergic reaction attribute compound similar chemical biologic composition sunitinib . Patients receive concurrent treatment anticancer therapy give paraganglioma pheochromocytoma therapy investigational anticancer agent . Patients receive prior treatment antiangiogenic agent multitargeted tyrosine kinase inhibitor ineligible . Patients follow cardiovascular finding exclude : QTc prolongation significant ECG abnormality . Current history Class III IV heart failure define NYHA functional classification system Patients prior anthracycline exposure , previous central thoracic radiation include heart radiation port , history NYHA Class II cardiac function . Poorly control hypertension Myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within 12 month prior study entry History venous thrombosis pulmonary embolism past 3 month History cerebrovascular accident ( CVA ) transient ischemic attack within 12 month prior study entry Patients require use therapeutic dos coumarinderivative anticoagulant warfarin Patients bowel obstruction condition impair ability swallow retain sunitinib tablet . Use agent proarrhythmic potential permit study . Must able stop prohibit select CYP3A4 inhibitors/inducers prior start sunitinib Patients preexist hypothyroidism prior enrolment ineligible unless euthyroid medication . Pregnant lactate woman , positive pregnancy test , woman childbearing potential agree use adequate contraception prior study entry duration study participation . Known HIVpositive patient combination antiretroviral therapy Greater +1 proteinuria urinary dipstick also &gt; 1g urinary protein/24hrs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PARAGANGLIOMA</keyword>
	<keyword>PHEOCHROMOCYTOMA</keyword>
	<keyword>SUNITINIB</keyword>
	<keyword>PHASE II</keyword>
	<keyword>Metastatic locally advance malignant paraganglioma</keyword>
	<keyword>Metastatic locally advance malignant pheochromocytoma</keyword>
</DOC>